Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gallium-68 RM2 - Life Moleuclar Imaging

Drug Profile

Gallium-68 RM2 - Life Moleuclar Imaging

Alternative Names: 68Ga-Bombesin; [(68)Ga]-labelled bombesin; [68GA]DOTA-4-AMINO-1-CARBOXYMETHYLPIPERIDINE-D-PHE-GLN-TRP-ALA-VAL-GLY-HIS-STA-LEU-NH2; [68Ga]RM2; BAY 867548; Bombesin (68Ga) labelled; Gallium-68-bombesin

Latest Information Update: 05 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Developer Life Molecular Imaging; National Cancer Institute (USA); Stanford University; University Hospital of Bordeaux
  • Class Imaging agents; Neuropeptides; Oligopeptides; Organometallic compounds; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Bombesin receptor antagonists; Ionising radiation emitters; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Prostate cancer

Most Recent Events

  • 07 Mar 2022 Stanford University in collaboration with General electric completes a phase I/II trial in Prostate cancer (Diagnosis) in the US (IV) (NCT03949517)
  • 05 Mar 2021 Phase-II development is ongoing in France and USA (IV)
  • 29 May 2020 Efficacy and pharmacodynamics data from a phase II/III trial in Prostate cancer presented at the 56th Annual Meeting of the American Society of Clinical Oncology (ASC0-2020)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top